RNA Quote, Financials, Valuation and Earnings

EXACT Sciences Corp. has a net margin of -1398.33% compared to Avidity Biosciences, Inc.'s net margin of -2.3%. Avidity Biosciences, Inc.'s return on equity of -37.47% beat EXACT Sciences Corp.'s return on equity of -38%.

Avidity Biosciences, Inc. has a consensus price target of $74.00, signalling upside risk potential of 3.38%. On the other hand EXACT Sciences Corp. has an analysts' consensus of $103.67 which suggests that it could grow by 2.39%. Given that Avidity Biosciences, Inc. has higher upside potential than EXACT Sciences Corp., analysts believe Avidity Biosciences, Inc. is more attractive than EXACT Sciences Corp..

Avidity Biosciences, Inc. has a beta of 0.904, which suggesting that the stock is 9.581% less volatile than S&P 500. In comparison EXACT Sciences Corp. has a beta of 1.417, suggesting its more volatile than the S&P 500 by 41.664%.

Avidity Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EXACT Sciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avidity Biosciences, Inc. pays -- of its earnings as a dividend. EXACT Sciences Corp. pays out -- of its earnings as a dividend.

Avidity Biosciences, Inc. quarterly revenues are $12.5M, which are smaller than EXACT Sciences Corp. quarterly revenues of $850.7M. Avidity Biosciences, Inc.'s net income of -$174.4M is lower than EXACT Sciences Corp.'s net income of -$19.6M. Notably, Avidity Biosciences, Inc.'s price-to-earnings ratio is -- while EXACT Sciences Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avidity Biosciences, Inc. is 450.42x versus 6.16x for EXACT Sciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -1398.33% compared to Avidity Biosciences, Inc.'s net margin of 31.72%. Avidity Biosciences, Inc.'s return on equity of -37.47% beat Eli Lilly & Co.'s return on equity of 106.26%.

Avidity Biosciences, Inc. has a consensus price target of $74.00, signalling upside risk potential of 3.38%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,045.59 which suggests that it could grow by 1.16%. Given that Avidity Biosciences, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Avidity Biosciences, Inc. is more attractive than Eli Lilly & Co..

Avidity Biosciences, Inc. has a beta of 0.904, which suggesting that the stock is 9.581% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Avidity Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Avidity Biosciences, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Avidity Biosciences, Inc. quarterly revenues are $12.5M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Avidity Biosciences, Inc.'s net income of -$174.4M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Avidity Biosciences, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 51.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avidity Biosciences, Inc. is 450.42x versus 15.86x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Intellia Therapeutics, Inc. has a net margin of -1398.33% compared to Avidity Biosciences, Inc.'s net margin of -735.19%. Avidity Biosciences, Inc.'s return on equity of -37.47% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.

Avidity Biosciences, Inc. has a consensus price target of $74.00, signalling upside risk potential of 3.38%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $24.85 which suggests that it could grow by 147.59%. Given that Intellia Therapeutics, Inc. has higher upside potential than Avidity Biosciences, Inc., analysts believe Intellia Therapeutics, Inc. is more attractive than Avidity Biosciences, Inc..

Avidity Biosciences, Inc. has a beta of 0.904, which suggesting that the stock is 9.581% less volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.133, suggesting its more volatile than the S&P 500 by 113.344%.

Avidity Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avidity Biosciences, Inc. pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.

Avidity Biosciences, Inc. quarterly revenues are $12.5M, which are smaller than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. Avidity Biosciences, Inc.'s net income of -$174.4M is lower than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, Avidity Biosciences, Inc.'s price-to-earnings ratio is -- while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avidity Biosciences, Inc. is 450.42x versus 16.51x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novartis AG has a net margin of -1398.33% compared to Avidity Biosciences, Inc.'s net margin of 28.26%. Avidity Biosciences, Inc.'s return on equity of -37.47% beat Novartis AG's return on equity of 33.87%.

Avidity Biosciences, Inc. has a consensus price target of $74.00, signalling upside risk potential of 3.38%. On the other hand Novartis AG has an analysts' consensus of $134.88 which suggests that it could grow by 0.87%. Given that Avidity Biosciences, Inc. has higher upside potential than Novartis AG, analysts believe Avidity Biosciences, Inc. is more attractive than Novartis AG.

Avidity Biosciences, Inc. has a beta of 0.904, which suggesting that the stock is 9.581% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.525, suggesting its less volatile than the S&P 500 by 47.542%.

Avidity Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novartis AG offers a yield of 2.99% to investors and pays a quarterly dividend of $3.99 per share. Avidity Biosciences, Inc. pays -- of its earnings as a dividend. Novartis AG pays out 55.39% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Avidity Biosciences, Inc. quarterly revenues are $12.5M, which are smaller than Novartis AG quarterly revenues of $13.9B. Avidity Biosciences, Inc.'s net income of -$174.4M is lower than Novartis AG's net income of $3.9B. Notably, Avidity Biosciences, Inc.'s price-to-earnings ratio is -- while Novartis AG's PE ratio is 18.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avidity Biosciences, Inc. is 450.42x versus 4.84x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.